Since the interaction of PML and HBsAg could be a predictive factor, reanalysis of the previous interferon and As2O3 trials is warranted in HBV-related HCC patients that are stratified by the HBsAg/PML expression ratio. This evidence concerns the gene PML and hepatocellular carcinoma.